Advertisement
UK markets close in 1 hour 10 minutes
  • FTSE 100

    8,036.74
    +12.87 (+0.16%)
     
  • FTSE 250

    19,736.36
    +136.97 (+0.70%)
     
  • AIM

    754.09
    +4.91 (+0.66%)
     
  • GBP/EUR

    1.1627
    +0.0038 (+0.33%)
     
  • GBP/USD

    1.2452
    +0.0101 (+0.82%)
     
  • Bitcoin GBP

    53,729.86
    +514.21 (+0.97%)
     
  • CMC Crypto 200

    1,430.92
    +16.16 (+1.14%)
     
  • S&P 500

    5,054.45
    +43.85 (+0.88%)
     
  • DOW

    38,403.75
    +163.77 (+0.43%)
     
  • CRUDE OIL

    82.02
    +0.12 (+0.15%)
     
  • GOLD FUTURES

    2,341.20
    -5.20 (-0.22%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    18,078.86
    +218.06 (+1.22%)
     
  • CAC 40

    8,082.24
    +41.88 (+0.52%)
     

Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot

Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot

WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Tuesday reported fiscal second-quarter earnings of $4.1 million.

On a per-share basis, the Watertown, Massachusetts-based company said it had net income of 20 cents.

The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 9 cents per share.

The biotechnology company posted revenue of $39.6 million in the period, which fell short of Street forecasts. Four analysts surveyed by Zacks expected $40.3 million.

Enanta Pharmaceuticals shares have climbed 24% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $87.50, a decline of 16% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ENTA at https://www.zacks.com/ap/ENTA